AVR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AV

Mkt Cap

$590.1M

Volume

875.36K

Next Earnings

November 11th

Loading chart

AV

AVRAnteris Technologies Global Corp. Common Stock

AVR

Pay with—

Available Balance0.00

AV

Mkt Cap

$619.8M

Volume

875.36K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Anteris to Present at September Healthcare Investor ConferencesAnteris Technologies Global Corp. announced that Vice Chairman and CEO Wayne Paterson will present at three major healthcare conferences in September 2026: Cantor Global Healthcare Conference (Sept 9), Wells Fargo 21st Annual Healthcare Conference (Sept 10), and Morgan Stanley 24th Annual Global Healthcare Conference (Sept 14). The company is showcasing its DurAVR® Transcatheter Heart Valve, a biomimetic device designed to treat aortic stenosis.GlobeNewswire Inc. · Aug 31, 2026

Anteris Advances Global PARADIGM Expansion with French Regulatory ClearanceAnteris Technologies announced it has received full regulatory clearance from France's ANSM to conduct the PARADIGM Trial for its DurAVR® Transcatheter Heart Valve. The prospective randomized controlled trial will enroll approximately 1,000 patients to evaluate the safety and effectiveness of DurAVR® compared to commercially available TAVR devices, with patient recruitment now commencing at leading French centers.GlobeNewswire Inc. · Jun 8, 2026

Anteris Announces Results for the First Quarter of 2026Anteris Technologies reported Q1 2026 results with $320 million in capital raises completed to support the PARADIGM Trial for its DurAVR® THV System. The company achieved U.S. patient enrollment commencement post-quarter and secured CMS reimbursement coverage, facilitating U.S. site activation. Net operating cash outflows were $28.7 million, primarily driven by clinical, regulatory, and manufacturing activities.GlobeNewswire Inc. · May 12, 2026

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM TrialAnteris Technologies announced it has secured U.S. Medicare reimbursement eligibility for its PARADIGM Trial under a Coverage with Evidence Development model. The trial will evaluate the safety and effectiveness of the company's DurAVR® Transcatheter Heart Valve against commercially available alternatives in approximately 1,000 patients. This milestone is expected to accelerate U.S. site activation and operational momentum.GlobeNewswire Inc. · Apr 28, 2026

Anteris Reports 2025 Financial Results and Provides Corporate UpdateAnteris Technologies reported 2025 financial results with net operating cash outflows of $77.8 million, driven by increased clinical and manufacturing activities. The company initiated the global PARADIGM Trial for its DurAVR® transcatheter heart valve, received FDA IDE approval, and completed a strategic $320 million capital raise including investment from Medtronic to support commercialization efforts.GlobeNewswire Inc. · Feb 26, 2026

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital RaisesAnteris Technologies completed a $90 million strategic investment from Medtronic and a $230 million underwritten public offering, totaling $320 million in capital. The funding will support execution of the global PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve for treating aortic stenosis.GlobeNewswire Inc. · Jan 22, 2026

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common StockAnteris Technologies closed a $320 million capital raise consisting of a $200 million underwritten public offering of 40 million shares at $5.75 per share and a $120 million private placement to Medtronic. The company will use proceeds to advance its DurAVR® Transcatheter Heart Valve in the PARADIGM Trial, expand manufacturing capabilities, and fund research and development for v2vmedtech.GlobeNewswire Inc. · Jan 22, 2026

Anteris Technologies Global Corp. Announces Pricing of $200 Million Public OfferingAnteris Technologies announced a $200 million public offering of 34.78 million shares at $5.75 per share, with an expected closing on January 22, 2026. Additionally, Medtronic agreed to invest up to $90 million in a private placement representing 16-19.99% ownership. Proceeds will fund the PARADIGM Trial for the DurAVR® Transcatheter Heart Valve, manufacturing expansion, and R&D for v2vmedtech.GlobeNewswire Inc. · Jan 21, 2026

Anteris Announces Results for the Third Quarter of 2025Anteris Technologies received FDA approval to commence patient recruitment for its PARADIGM Trial, evaluating the DurAVR® Transcatheter Heart Valve across the United States, Europe, and Canada. The company advanced regulatory activities, strengthened operational systems, and reported $59.3 million in net operating cash outflows for the first nine months of 2025.GlobeNewswire Inc. · Nov 12, 2025

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)Anteris Technologies has enrolled and treated the first patients in its global PARADIGM Trial for the DurAVR® Transcatheter Heart Valve, a study comparing the device's safety and effectiveness against existing transcatheter aortic valve replacements.GlobeNewswire Inc. · Oct 27, 2025

to start trading

AV

AVRAnteris Technologies Global Corp. Common Stock

AVR

Pay with—

Available Balance0.00

Your PositionYou don't own any AVR yet.

Related Tickers

Earnings